Servier Acquires Edgewise Therapeutics' Muscular Dystrophy Business to Advance Rare Neurological Disease Treatment
Servier, a pharmaceutical company, has completed the acquisition of Edgewise Therapeutics' muscular dystrophy business. This strategic move aims to bolster Servier's research portfolio and expertise in rare neurological diseases, with a specific focus on Becker and Duchenne muscular dystrophies. The acquisition is part of Servier's broader goal to become a global leader in this field by 2030, prioritizing genetic neurological diseases that are severely disabling. Becker muscular dystrophy is a rare, X-linked genetic disorder affecting approximately one in 18,500 live male births, leading to progressive muscle wasting. It impacts an estimated 5,000 to 6,000 male patients in the U.S. and around 35,000 people across the U.S., EU4, Japan, and China. The disease is caused by mutations in the DMD gene, which is responsible for producing dystrophin, a protein crucial for proper muscle function. Currently, there is no approved treatment to slow the progression of Becker muscular dystrophy, and management primarily...
